Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: A retrospective evaluation of safety and efficacy

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2328-2334

  Gopal, Ajay K ^a   Bartlett, Nancy L ^b   Forero Torres, Andres ^c   Younes, Anas ^d   Chen, Robert ^e   Friedberg, Jonathan W ^f   Matous, Jeffrey V ^g   Shustov, Andrei R ^h   Smith, Scott E ⁱ   Zain, Jasmine ^j   O'Meara, Megan M ^k   Fanale, Michelle A ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g Rocky Mountain Blood and Marrow Transplant Program   (United States)

^h UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j NEW YORK UNIVERSITY   (United States)

^k SEATTLE GENETICS INC   (United States)

more..

Author keywords

Elderly; Hodgkin lymphoma; Lymphomas; T cell lymphoma

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER RECURRENCE; CHILD; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; VOMITING; YOUNG ADULT; AGE; METABOLISM; MORTALITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902483882     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.876496     Document Type: Article

References (33)

1. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
2. Kennedy BJ, Loeb V Jr, Peterson VM, et al. National survey of patterns of care for Hodgkin's disease. Cancer 1985;56:2547-2556.
3. Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 2012;30:3939-3946.
4. Stark GL, Wood KM, Jack F, et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 2002;119:432-440.
5. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 2009;71:222-232.
6. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration:a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626-4631.
7. Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013;31:1522-1529.
8. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005;23:5052-5060.
9. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012;119:692-695.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
11. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999;94:33-38.
12. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 2013;161:76-86.
13. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858.
14. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-3695.
15. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742.
16. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-1465.
17. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-784.
18. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
19. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma:results of a phase II study. J Clin Oncol 2012;30:2190-2196.
20. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248-255.
21. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
22. Bartlett N, Brice P, Chen RW, et al. Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study. J Clin Oncol 2012;30(15 Suppl.): Abstract 8027.
23. Han TH, Chen R, Advani R, et al. Brentuximab vedotin does not prolong the QT/QTc interval in patients with CD30-positive lymphomas. Clin Pharmacol Drug Dev 2012;1:a1393219.
24. Han TH, Grove LE, Lynch CF. Effect of renal impairment on the pharmacokinetics of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignacies. Presented at American Society for Clinical Pharmacology Annual Meeting, 6-9 March 2013, Indianapolis, IN, USA.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
27. Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004;4:94.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
29. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr 2004;32:150-157.
30. Balducci L. Anemia, cancer, and aging. Cancer Control 2003;10:478-486.
31. Mold JW, Vesely SK, Keyl BA, et al. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract 2004;17:309-318.
32. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1:18-24.
33. Evens AM, Hong F. How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 2013;31:1502-1505.